# Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

> **NCT02406521** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 30 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** Sorafenib
- **DRUG:** Radium-223

## Key facts

- **NCT ID:** NCT02406521
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2017-12
- **Final completion:** 2019-12-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02406521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02406521, "Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02406521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*